SGLT2i and GLP1RA show no differential risk for diabetic retinopathy in T2D patients with CKD stages 3-4.
Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes.
Abstract
SGLT2 inhibitors and GLP-1 receptor agonists demonstrated no significant difference in incident nonproliferative diabetic retinopathy or progression in T2D patients with CKD stages 3-4.
